



# SERINCs: novel restriction factors counteracted by HIV Nef




Heinrich Göttlinger, MD  
Molecular, Cell and Cancer Biology  
UMass Medical School



# HIV-1 Genes and Proteins



# Intrinsic cellular-defense against retroviruses



# Role of HIV-1 Nef

- Crucial for high viral loads and disease progression
- In cell culture:
  - Robustly down-regulates CD4
  - Down-regulates MHC-I
  - **Enhances infectivity**
    - CD4-independent
    - No obvious effect on virion
    - Producer cell-dependent
    - Effect depends on **dynamin, clathrin, AP2**
    - Effect mimicked by **MLV glycoGag**
    - Effect determined by **Env**

# ARTICLE

doi:10.1038/nature15399

---

---

## **HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation**

Annachiara Rosa<sup>1\*</sup>, Ajit Chande<sup>1\*</sup>, Serena Ziglio<sup>1\*</sup>, Veronica De Sanctis<sup>2</sup>, Roberto Bertorelli<sup>2</sup>, Shih Lin Goh<sup>3</sup>, Sean M. McCauley<sup>3</sup>, Anetta Nowosielska<sup>3</sup>, Stylianos E. Antonarakis<sup>4,5</sup>, Jeremy Luban<sup>3</sup>, Federico Andrea Santoni<sup>4</sup> & Massimo Pizzato<sup>1</sup>

# ARTICLE

doi:10.1038/nature15400


---

---

## **SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef**

Yoshiko Usami<sup>1\*</sup>, Yuanfei Wu<sup>1\*</sup> & Heinrich G. Göttlinger<sup>1</sup>









provided by Massimo Pizzato

# MLV glycoGag has Nef-like effect on HIV infectivity


5' end of murine leukemia virus:






# HIV-1 infectivity enhancement by Nef and glycoGag


Dependence on producer cell type:



Dependence on clathrin-mediated endocytosis:



- ❑ HIV Nef and MLV glycoGag similarly enhance HIV-1 infectivity
- ❑ Effects are similarly dependent on producer cell type
- ❑ Effects exhibit a similar reliance on clathrin-mediated endocytosis




Proteins identified only in Nef<sup>-</sup> virions


	Protein Symbol	Gradient Fraction	Total Spectrum Count	% Coverage
Experiment 1	<b>SERINC3</b>	8	7	15
		9	11	16
	STOM	8	2	7
		9	6	16
		PFKP	8	5
Experiment 2	<b>SERINC3</b>	9	10	8
		8	5	9
	STOM	8	5	9
		9	9	9

# Inhibition of SERINC incorporation by Nef correlates with infectivity enhancement


## Inhibition of SERINC3 incorporation



## Inhibition of SERINC5 incorporation




## Enhancement of HIV-1 infectivity





# Nef and glycoGag remove SERINC5 from the cell surface

## Effect on subcellular localization




## Effect on cell surface expression




# Exogenous SERINC5 specifically blocks HIV-1 Env-mediated infectivity

## Virus morphogenesis





## Virus infectivity




# Exogenous SERINC5 is counteracted by Nef and glycoGag

## Virus infectivity




## Expression of SERINC proteins in Jurkat cells



# Endogenous SERINC3 and SERINC5 synergistically restrict Nef<sup>-</sup> HIV-1 infectivity


## Virus infectivity







# SERINC depletion has negligible effects on HIV infectivity in the presence of Nef or glycoGag

## Infectivity of JurkatTAg-derived virus



# Exogenous SERINC5 blocks HIV-1 entry



# CRISPR/Cas9-mediated knockout of SERINC3 and SERINC5 in Jurkat-TAg cells

## SERINC3

Gene sequence

Target site A  
 TGT **GTATCGGATCAGCTTTGCCA** TGGCCATCT

JurkatTAg S3 -/- (1)

TGT **GTATCGGATCAGCTTTGCCA** TGGCCATCT (1 bp insertion)  
 TGT **GTATCG** TCT (20 bp deletion)

## SERINC5

Gene sequence



Target site A Target site B  
 GGT **GACACCTGTGAGAAGCTTGGT** GGGATATT .... /11.5 kb /.... GACAGCCA **CAC** TCGGGGCTCTTACAATC AGGGGT

JurkatTAg S3+5 -/- (1)


GGT **GACACCTGTGAGAAGCTTAGTG** TGGCTGTC.... /11.5 kb /.... AATATCC **ACC** GGGGCTCTTACAATC AGGGGT  
 GGT **GACACCTGTGAGAAGCTTGGT** GGGATATT.... /11.5 kb /.... GACAGCCA **CAC** A TCGGGGCTCTTACAATC AGGGGT

# Infectivity of Nef<sup>-</sup> HIV-1 produced in SERINC knockout JurkatTAg cells


## HIV-1-GFP (Nef<sup>-</sup>)








## Nef and glycoGag have negligible effects on HIV infectivity in double-KO cells lacking SERINC3 and SERINC5



# Re-expressed SERINC3 and SERINC5 restrict HIV-1 infectivity




# Nef counteracts inhibition of HIV-1 replication by SERINC3 and SERINC5







- Nef

SERINC3  
SERINC5

+ Nef or MLV glycoGag



Producer cell




Target cell





UMASS  
Medical School

AARON LAZARE  
MEDICAL RESEARCH  
BUILDING



**NIDA**  
NATIONAL INSTITUTE  
ON DRUG ABUSE